Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
Key Highlights
- ➤Q3 2026 financial results scheduled for November 4 after market close
- ➤Management webcast will discuss results and provide a corporate progress update
- ➤Revolution Medicines advances oral RAS(ON) inhibitors for RAS-addicted cancers
REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
Get started
Create a free account to read the full story.